The Mammalian Target of Rapamycin Pathway as a Potential Target for Cancer Chemoprevention
- 1Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland and 2CCS Associates, Mountain View, California
- Requests for reprints:
Levy Kopelovich, National Institutes of Health, National Cancer Institute, Division of Cancer Prevention, Chemopreventive Agent Development Research Group, 6130 Executive Blvd. Bethesda, MD 20892. Phone: 301-94-0467; Fax: 301-402-0553. E-mail: lk94c{at}nih.gov
Abstract
The mammalian target of rapamycin (mTOR) is a key signaling node coordinating cell cycle progression and cell growth in response to genetic, epigenetic, and environmental conditions. Pathways involved in mTOR signaling are dysregulated in precancerous human tissues. These findings, together with the intriguing possibility that mTOR suppression may be associated with antitumor actions of caloric restriction, suggest that mTOR signaling may be an important target for chemopreventive drugs. (Cancer Epidemiol Biomarkers Prev 2007;16(7):1330–40)
Footnotes
-
- Accepted April 16, 2007.
- Received January 14, 2007.
- Revision received March 24, 2007.
